Research On Financing Risk Control Of Biopharmaceutical Companies On The Growth Enterprise Market In My Country

Bio-pharmaceutical industry as a national key of high-tech industries supported the development humans' live.The development and promulgation of the 13th Five-Year Plan for National Economic and Social Development of the People's Republic of China(hereinafter referred to as the "13th Five-Year Plan")also put forward new development goals for the whole biomedical industry,that is,to further promote the whole industry International development.Since the creation of the GEM in 2009,as a good momentum of development of bio-pharmaceutical companies began to active in the GEM,with the accelerated economic globalization,in order to maintain the normal production and operation of enterprises,enterprises must be a strong financial support.The control and management of the financing risks in the bio-pharmaceutical corporations in the GEM determines the success or failure of the corporate finance,which further affects the survival and development of the enterprises.Therefore,it is very important to learn the financing risk control of the bio-pharmaceutical enterprises in the GEM.This paper is based on the relevant theories of financing,the characteristics and classification of financing and the financing risks.Then,the characteristics of the bio-pharmaceutical industry are analyzed,and the financing status of the industry is analyzed and analyzed to analyze the financing risks of bio-pharmaceutical enterprises.Based on the proposed rationalization proposals.